Beckman Coulter Life Sciences has launched its new Valita Aggregation Pure assay, offering rapid, high-throughput protein aggregation detection and quantification, providing robust aggregation data in as little as 15 minutes.
Traditional workflows in monoclonal antibody production require long wait times of up to six hours to determine protein aggregation levels. The new Valita Aggregation Pure assay is a plate-based 96-well screening tool that cuts through the clutter, delivering a rapid solution that is among the fastest and simplest aggregation detection tools on the market, and is compatible with high-performance microplate readers with fluorescence polarisation functionality.
“Processing thousands of samples to generate a commercially viable cell line is a complex and tedious process that can slow laboratory workflows,” said Dr Elisa Nent, Global Product Manager - Cell Health. “We continue to hear the critical need to rapidly measure antibody aggregation faster than traditional DLS/SLS and HPLC-SEC methods. Our innovation slashes manual steps, the need for additional reagents, and added expense; all in a fraction of the time. We’re confident this will allow laboratory staff to get results faster and focus their efforts on critical research goals.”
The new assay enhances the process development workflow by enabling detection and quantification of antibody aggregation at any stage of time. In less than 15 minutes, aggregation can be quantified by simply adding purified samples to the plate, incubating at room temperature, and measuring aggregation using a plate reader. Available as 96-well plates and validated with samples concentrated between 200-2,000 mg/L, with a detection limit of 0.5% aggregation at 1,000 mg/L, it enables rapid, high-throughput protein aggregation analysis.
Learn more about the Valita Aggregation Pure Assay by clicking here.